AVE 0.00% 0.3¢ avecho biotechnology limited

Ann: Appendix 4E and Annual Report 31 December 2021, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,650 Posts.
    lightbulb Created with Sketch. 777
    Let's be positive...
    AVE have 3.2 million in cash or 4 quarters of funding

    potential revenue
    - SAAS 1.38 million licenses
    - medterra 1.1 million (very optimistic)
    - 1 million RD rebate
    - Ashland $700000 (real surprise this income is here and growing???)
    - let's say they sell 1 mill worth of TPM to SAAS and medterra that would be a profit of approx 600000
    - get a cut of SAAS of 200000

    end of year approx 4.8 million revenue.

    that's a lot that has to go right.
    they certainly need two to three more similar licensing agreements to come to fruition along with insomnia deals before you would feel comfortable with AVE long term future.

    if things turn bad then but September they are looking to raise again.

    my gut tells me there will be a couple of positive announcements relatively soon.
    if they result in a sp spoke if expect a cash raise under the pretence of funding growth opportunities.
    if SP gets anywhere near 6 cents be prepared for horizon to sell its position.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.